Keywords: strong, first-half, pharma, sales, aventis, fuelled, growth
Strong first-half pharma sales for Aventis, fuelled by 40% growth in the US
Article | 28 July 2000
Franco-German Aventis SA reported first-half 2000 sales up 11.6% at10.25 billion euros ($9.56 billion), while Aventis Pharma turnover rose 17.6% to 7.79 billion euros, with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
